GenScript USA Inc., the world's leading research reagent provider, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit.

Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today announced that Howard Li, Ph.D., Preclinical Research Scientist, will present a late-breaking virtual poster at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced updated clinical results from the combination arm of the Company’s ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA^®  (pembrolizumab), Merck’s anti-PD-1 therapy in non-small cell lung cancer (NSCLC).

In an expansion cohort of a phase I CHRYSALIS study, the RP2CD (recommended phase 2 combination dose) of amivantamab antibody combined with 3rd generation EGFR TKI lazertinib to exam patients in osimertinib resistant(n=45) or treatment-naïve(n=20) EGFR-positive (exon 19 deletions and L858R) NSCLCs.

ERBB2 exon 20 insertion accounts for 2-3% of the total mutations of non-small cell lung cancer. However, there is still an unmet need for treating patients with this kind of mutation. The phase 2 ZENITH20 trial is aimed to study the activity of poziotinib in NSCLC patients with either an EGFR exon 20 insertion or an ERBB2 exon 20 insertion.

Urothelial carcinoma (UC) is one of the malignant diseases with a poor five-year survival rate. Platinum-based regimen is the major treatment option for patients with UC. Recently, immune checkpoint inhibitors had been demonstrated anti-tumor activity in UC. Avelumab is an anti–PD-L1 antibody that has been approved with first-line maintenance treatment in UC followed the phase 3 JAVELIN Bladder 100 trial.N/A

Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today announced that Sonny Hsiao, Ph.D., chief executive officer, will present a corporate overview at the upcoming 7th Annual China Healthcare Summit on November 9, 2020.

N/A

Nanotein Technologies, Inc., an innovative startup biotechnology company in the San Francisco Bay Area, and Polaris Group, a developer of novel treatments for cancer, announced today they have entered into a strategic partnership to advance Nanotein’s protein-based solutions for superior cellular therapy manufacturing.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock.